Board of Directors & Committee Composition
Cam L. Garner
Director and Chairman of the Board
Mr. Garner is one of our co-founders and has served as a member of our board of directors since our inception in May 2004, and as chairman of our board of directors since July 2004. Mr. Garner was Chief Executive Officer of Dura Pharmaceuticals, Inc., a pharmaceutical company, from 1989 to 1995 and Chairman and Chief Executive Officer of Dura from 1995 until it was sold to Elan Pharmaceuticals, Inc. in November 2000. Mr. Garner also co-founded specialty pharmaceutical companies Verus Pharmaceuticals, Inc., Somaxon Pharmaceuticals, Inc., Zogenix, Inc., Evoke Pharma, Inc., Elevation Pharmaceuticals, Inc., Meritage Pharma, Inc., DJ Pharma (sold to Biovail Corporation in 2000) and Xcel Pharmaceuticals, Inc. (acquired by Valeant Pharmaceuticals International in March 2005). Mr. Garner is currently a member of the board of directors of privately-held Aegis Therapeutics, Inc., and he is chairman and a member of the board of directors of publicly held Zogenix and three other privately-held companies: Evoke, Elevation and Meritage. He previously served on the board of directors of Somaxon, Favrille, Inc., Pharmion Corporation, SkinMedica, Inc., Verus Pharmaceuticals and Xcel Pharmaceuticals. Mr. Garner received an M.B.A. from Baldwin-Wallace College and a B.A. in biology from Virginia Wesleyan College.
Mr. Atwood has served as a member of our board of directors since March 2006. Since 1999, Mr. Atwood has served as a Managing Director of Versant Ventures I, LLC, Versant Ventures II, LLC and Versant Ventures III, LLC. (Versant Ventures is a venture capital firm focusing on healthcare that he co-founded). Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. He was also founder, President and Chief Executive Officer of Glycomed, Inc. Mr. Atwood is currently a member of the board of directors of Helicos Biosciences Corp., a publicly-held company, where he is also a member of the audit committee, and Trius Therapeutics, Inc., where he is also a member of the audit committee. Mr. Atwood is also currently a member of the board of directors of six privately-held companies: Clovis Oncology, Inc., Five Prime Therapeutics, Inc., Immune Design Corporation, OpGen, Inc., PhaseRx, Inc., and Veracyte, Inc. He was previously a member of the board of directors of ForteBio, Inc. and Pharmion Corporation. Mr. Atwood also serves on the Dean’s Advisory Board, School of Biological Sciences, University of California, Irvine. Mr. Atwood received a B.S. in biological sciences from the University of California, Irvine, an M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University.
Samuel L. Barker, Ph.D.
Dr. Barker has served as a member of our board of directors since August 2006. In March 2001, Dr. Barker co-founded Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies, and has served as a principal since that time. Dr. Barker also served as President and Chief Executive Officer of Clearview Projects from July 2003 to November 2004. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as Executive Vice President, Worldwide Franchise Management and Strategy during 1998, President, United States Pharmaceuticals from 1992 to 1997, and President, Bristol-Myers Squibb Intercontinental Commercial Operations from 1990 to 1992. Prior to 1990, Dr. Barker held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker is currently a member and chairman of the board of directors of Lexicon Pharmaceuticals Inc., a publicly-held biopharmaceutical company, where he also serves as chairman of the audit committee. Previously, Dr. Barker was a member of the board of directors of Atherogenics, Inc. Dr. Barker received a B.S. from Henderson State College, an M.S. from the University of Arkansas and a Ph.D. from Purdue University.
James C. Blair, Ph.D.
Dr. Blair has served as a member of our board of directors since September 2005. Since 1985, Dr. Blair has served as a Partner of Domain Associates, L.L.C., a venture capital management company focused on life sciences. In the course of his more than forty years’ experience in the venture capital industry, he has been involved in the creation and successful development of over forty life sciences ventures, including Amgen, Inc., Aurora Biosciences Corporation, Amylin Pharmaceuticals, Inc., Applied Biosystems, Inc., Dura Pharmaceuticals, GeneOhm Sciences, Inc., Molecular Dynamics, Inc., NuVasive, Inc., Volcano Corporation, and Pharmion Corporation. Dr. Blair is currently a member of the board of directors of Zogenix, Inc., where he also serves on the compensation committee, seven privately-held companies and the Prostate Cancer Foundation, a non¬profit organization. He serves on the advisory boards of the Department of Molecular Biology at Princeton University, the Department of Biomedical Engineering at the University of Pennsylvania, the Stevens Institute for Innovation at the University of Southern California, and the Division of Chemistry and Chemical Engineering at the California Institute of Technology. Dr. Blair received a B.S.E. degree from Princeton University and an M.S.E. & Ph.D. from the University of Pennsylvania.
Ms. DeBuono has served as a member of our board of directors since August 2013. Since October 2011, Ms. DeBuono has been a partner of FLG Partners, LLC, a leading CFO consulting services firm. Prior to joining FLG Partners, Ms. DeBuono served as President, CEO and member of the board of directors of Coapt Systems, Inc., and as Chief Financial Officer of Thermage, Inc. Previously, Ms. DeBuono served as consulting chief financial officer, executive vice president, chief operations officer and general counsel of several medical technology, consumer products, and technology companies. Ms. DeBuono is currently a member of the board of directors of two privately-held companies, Cradle Holdings, Inc., and VenX LLC. She previously served as a member of the board of directors and audit committee chair of two public companies, VISX, Inc. and InVivo Medical Diagnostics, Inc., and as a member of the board of two privately-held companies, Coapt Systems, Inc., and Alpha Orthopaedics, Inc. Ms. DeBuono is also a co-founder and co-chair of the MAIA Foundation, Inc., a non-profit 501(c)(3) corporation. Ms. DeBuono received a B.A. from Duke University, an M.A. from Stanford University and a J.D. from the New York University School of Law, and is a member of the State Bar of California.
Michael L. Eagle
Mr. Eagle has served as a member of our board of directors since March 2010. Mr. Eagle served as Vice President of Manufacturing for Eli Lilly and Company from 1994 through 2001 and held a number of executive management positions with Eli Lilly and its subsidiaries throughout his career there. Since retiring from Eli Lilly, he has served as a founding member of Barnard Life Sciences, LLC. Mr. Eagle is currently a member of the boards of directors of Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, where he also serves on the audit and compensation committees. Previously, he was a member of the board of directors of Favrille, Inc., Fusion Medical Technologies, Inc, Micrus Endovascular Corporation and Xtent, Inc. He also currently serves on the Board of Trustees of the La Jolla Playhouse and Futures for Children. Mr. Eagle received his B.S. degree in mechanical engineering from Kettering University and an M.B.A. from the Krannert School of Management at Purdue University.
Alan D. Frazier
Mr. Frazier has served as a member of our board of directors since March 2006. In 1991, Mr. Frazier founded Frazier Healthcare Ventures, a venture capital firm, and has served as the managing partner since its inception. From 1983 to 1991, Mr. Frazier served as Executive Vice President, Chief Financial Officer and Treasurer of Immunex Corporation, a biopharmaceutical company. From 1980 to 1983, Mr. Frazier was a principal in the Audit Department of Arthur Young & Company, which is now Ernst & Young LLP. Mr. Frazier is currently a member of the board of directors of Alexza Pharmaceuticals, Inc., a publicly-held specialty pharmaceutical company, where he also serves on the audit committee, and two privately-held companies: Ascension Orthopedics, Inc., a medical device company, and TridentUSA Health Services, LLP, a nationwide provider of bedside diagnostics to alternate site facilities. Previously, he was a member of the board of directors of Rigel Pharmaceuticals, Inc. He is also a member of the University of Washington Medicine Board, the University of Washington Medicine Strategic Initiatives Committee and the Board of Directors of the Washington Biotechnology and Biomedical Association. Mr. Frazier also serves on the Board of Trustees of the Western Washington University Foundation, and Amara Parenting and Adoption Services. Mr. Frazier received a B.A. in economics from the University of Washington.
Stephen L. Newman, M.D.
Dr. Newman has served as a member of our board of directors since March 2013. Dr. Newman served in positions of increasing responsibility with Tenet Healthcare Corporation from 1999 until his retirement in June 2012, including most recently as Vice Chairman from January 2012 until June 2012. He also served as Corporate Chief Operating Officer and Executive Vice President of Tenet Healthcare Corporation, Chief Executive Officer of Tenet HealthSystem, California, and as Senior Vice President, Gulf States Region, of Tenet HealthSystem. Prior to joining Tenet, Dr. Newman held executive positions at Columbia/HCA, Inc., and served as Senior Vice President and Chief Medical Officer of Touro Infirmary in New Orleans. Earlier in his career, Dr. Newman was an Associate Professor of Pediatrics and Medicine at Wright State University School of Medicine, and Director of Gastroenterology and Nutrition Support at Children’s Medical Center in Dayton, Ohio. Dr. Newman is currently a member of the Labor, Education and Healthcare Council of the Federal Reserve Bank of Atlanta, and a member of the Board of Directors of Optimer Pharmaceuticals, Inc., and Hansen Medical, Inc. He holds a bachelor’s degree from Rutgers University, an M.B.A. from Tulane University and a medical degree from the University of Tennessee. Dr. Newman completed his internship, residency and fellowship at Emory University School of Medicine, and has also completed the Advanced Management Program at the University of Pennsylvania’s Wharton School of Business.
Todd W. Rich, M.D.
Dr. Rich has served as a member of our board of directors since August 2008. Dr. Rich is currently Senior Vice President and Global Head of Clinical Operations and Quality of Genentech, Inc., a leading biotechnology company. From July 2006 until June 2009, Dr. Rich served as Vice President, Development Regulatory, Medical Information, Drug Safety, Quality and Compliance of Genentech. He has served in various other leadership positions with Genentech since 1992, including as Vice President, Clinical and Commercial Regulatory Affairs from April 2005 to June 2006, as Senior Director, Clinical Regulatory Affairs from September 2001 to March 2005, as Senior Director, Product Development from 2000 to September 2001, as Director of Product Experience from 1997 to 2000, and as Senior Manager, New Product Planning and Health Economics from 1992 to 1997. Dr. Rich received a B.A. in biology from Amherst College, an M.D. from Wayne State University, and an M.B.A. from Stanford University.
Theodore R. Schroeder
President, Chief Executive Officer and Director
Mr. Schroeder is one of our co-founders and has served as our President and Chief Executive Officer and as a member of our board of directors since our inception in May 2004. From August 2002 to February 2004, he served as Senior Vice President, North American Sales and Marketing, of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company. From February 2001 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan. Mr. Schroeder held the position of Senior Director of Marketing Hospital Products at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company, from May 1999 to November 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder is currently a member of the board of directors of Trius Therapeutics, Inc., a public pharmaceutical company, where he is also a member of the compensation committee, and the Sharp HealthCare Foundation, a non-profit organization. Mr. Schroeder received a B.S. in management from Rutgers University.
Christopher J. Twomey
Mr. Twomey has served as a member of our board of directors since July 2006. Mr. Twomey joined Biosite Incorporated, a medical diagnostic company, in March 1990 and served as its Senior Vice President, Finance and Chief Financial Officer until his retirement in 2007. From 1981 to 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. Mr. Twomey is currently a member of the board of directors of Senomyx, Inc., a publicly-traded company, where he serves as Chair of the audit committee and as a member of the governance and nominating committee. Mr. Twomey is also currently a director of two non-profit public benefit entities. Mr. Twomey was a certified public accountant from 1981 to 1991, and received a B.A. in business economics from the University of California at Santa Barbara.